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1. Introduction
Genetic predisposition for familial early-onset breast cancer 
accounts for approximately 5–10% of all breast cancers 
and 7–10% of all ovarian cancers (Emery et al. 2001). 
Mutations in two autosomal dominant genes, BRCA1 and 
BRCA2, have been linked to familial breast or breast and 
ovarian cancer (Hall et al. 1990; Miki et al. 1994; Wooster 
et al. 1995). Women who carry BRCA1 or BRCA2 mutations 
have an estimated lifetime risk of between 60% and
85% for developing breast cancer, and a lifetime risk of 
between 26% and 54% for developing ovarian cancer for 
BRCA1, and between 10% and 23% for BRCA2 (Easton et 
al. 1993; Brose et al. 2002; Antoniou et al. 2003; King et 
al. 2003).
Although their mechanism of action is not yet fully 
elucidated, it is assumed that these genes play a key role 
in important cellular pathways including response to DNA 
damage, transcription, and interaction with other proteins 
involved in DNA repair and apoptosis (Somasundaram 
2003; Narod and Foulkes 2004). Genetic testing helps
in identifying high-risk individuals in families with 
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Mutations in the BRCA1 and BRCA2 genes profoundly increase the risk of developing breast and/or ovarian cancer 
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inherited breast and/or ovarian cancer, and there are
various management options available for mutation 
carriers. 
Breast cancer is the most commonly occurring cancer 
among Indian women with a relative proportion ranging 
from 19.3% to 27.5% (ICMR 2006). Signifi cant variations 
in the relative contribution of mutations in BRCA1
and BRCA2 to the development of inherited familial breast 
and/or ovarian cancer have been reported (Liebens et al. 
2007). However, the contribution of mutations in these
two genes to breast cancer patients from Indian familial 
breast or ovarian cancer families remains relatively 
unexplored apart from a few small studies (Kumar et al. 
2002; Saxena et al. 2002; Rajkumar et al. 2003; Valarmathi 
et al. 2003, 2004; Hedau et al. 2004; Saxena et al. 2006). 
Hence, there is a need to screen a large number of samples
to investigate the role of BRCA1/BRCA2 gene mutations 
in the high-risk group of familial breast or ovarian cancer 
families. In this study, we report the screening for BRCA1 
and BRCA2 mutations in 61 breast and/or ovarian cancer 
patients with a positive family history of breast and/or 
ovarian cancer. 
2. Materials and methods
2.1 Patient selection
All the patients included in this study were treated at the 
Kidwai Memorial Institute of Oncology, Bangalore, India. 
Sixty-one patients with breast or ovarian or breast/ovarian 
cancer, each from a different family, were recruited for 
the study. These families were found to be not related to
each other as per the records. The families were derived 
from different parts of states located in south India inclu-
ding Kerala, Karnataka, Andra Pradesh and Tamil Nadu. 
Selected patients had at least one fi rst-degree relative 
affected with breast, ovarian or breast/ovarian cancer. 
There were 39 families with breast cancer (median age of 
patients 42 years), 10 families with ovarian cancer (median 
age of patients 33 years) and 12 families with breast and 
ovarian cancer (median age of patients 43.5 years). The age 
distribution of all patients ranged from 16 to 68 years with 
a mean of 42.5 years. Out of the 61 patients studied, there 
were 4 patients less than 25 years of age (6.55%), 26 patients 
in the age group of 25–40 years (42.6%) and 31 patients 
above 40 years (50.8%). Blood samples were collected from 
the patients and stored in acid–citrate–dextrose solution at 
–70°C. Blood samples collected from 100 age-matched, 
unrelated normal individuals without a family history of 
breast or ovarian cancer were used as controls. This study 
was approved by the Institutional Review Board of Kidwai 
Memorial Institute of Oncology (IRB No: PER/CAB-I/D-
1-13/01). 
2.2 Isolation of DNA from blood samples
Genomic DNA was isolated from 200 μl of each blood 
sample using a commercial DNA isolation kit (Qiagen, 
USA). For polymerase chain reaction (PCR), the DNA 
was diluted to 25 ng/μl and 4 μl was used in a 25 μl PCR 
reaction.
2.3 Preparation of PCR products
The sequence of primers for genomic DNA amplifi cation of 
BRCA1 and BRCA2 has already been described (Ganguly et 
al. 1997). A total of 33 and 52 PCR reactions were carried out 
to screen for BRCA1 and BRCA2, respectively. The primers for 
each exon were located at least 50 bp away from exon–intron 
boundaries. Non-coding exons were excluded from the study. 
The composition of the 10X buffer used except for exon 12 
of BRCA1 was 100 mM Tris-HCl pH 9.0, 15 mM MgCl
2
, 
500 mM KCl, 0.1% gelatin; for exon 12, the 10X buffer 
contained 100 mM Tris-HCl pH 8.8, 15 mM MgCl
2
, 750 mM 
KCl. PCR was performed in 25 μl solutions containing 100 
ng of genomic DNA, 1X PCR buffer, 100 μM dNTPs (Gibco 
BRL), 10 pmol of each primer (Sigma) and 0.5 U of Taq DNA 
polymerase (Bangalore Genei). Reactions were carried out in 
a thermal cycler (MyCycler, Biorad) as follows: 94°C for 5 
min, 35 cycles (94°C for 1 min, 55°C for 1 min, and 72°C for 
30 s) and 72°C for 10 min. For exon 13 and 11J of BRCA2, the 
annealing temperature was 56°C and 58°C, respectively. 
2.4 Conformation-sensitive gel electrophoresis 
For mutation analysis, we adopted conformation-sensitive 
gel electrophoresis (CSGE) as our preliminary screening 
method as described below. The CSGE method involves 
heteroduplex analysis of PCR products in a novel, mildly 
denaturing polyacrylamide gel matrix using a different cross-
linker, bis-acrolyl piperazine, instead of the conventional 
bis-acrylamide (Ganguly et al. 1993; Williams et al. 1995; 
Lakhotia and Somasundaram 2003). PCR products were 
denatured by heating at 98°C for 5 min and reannealed 
at 68°C for 1 h to generate heteroduplexes. The samples 
were loaded onto a polyacrylamide gel. The 1 mm thick 
10% polyacrylamide gel contained acrylamide (Sigma) and 
1,4-bis acryloyl piperazine (Fluka) cross-linker in the ratio 
of 99:1, 10% ethylene glycol (Sigma) and 15% formamide 
(Sigma) in 0.5X Tris taurine–EDTA buffer. 1X Tris taurine–
EDTA buffer contains 89 mM Tris, 28.5 mM taurine and 
0.2 mM EDTA pH 9.0. The samples were subjected to 
electrophoresis at 400 v for 16 h. The gels were stained with 
ethidium bromide (1 μg/ml) for 10 min and destained for 10 
min in double distilled water. PCR products were visualized 
by ultraviolet light and photographed. Samples displaying 
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abnormal CSGE profi les compared with that of the controls 
were identifi ed.
2.5 Direct sequencing of PCR products
Samples that showed an aberrant heteroduplex pattern 
were reamplifi ed from genomic DNA, the amplicons were 
purifi ed using QIAquick PCR purifi cation kit (Qiagen) and 
subjected to automated DNA sequencing (ABI 377; Applied 
Biosystems) using the manufacturer’s suggested protocols. 
Sense and antisense strand sequencing were done to confi rm 
all mutations.
3. Results
We screened the genomic DNA derived from 61 independent 
familial cases of both breast and/or ovarian cancer by a 
combination of heteroduplex analysis using CSGE and 
subsequent DNA sequencing. We found mutations in 17/61 
patients, thus bringing the total contribution of BRAC1 and 
BRCA2 to 28.0%. The total DNA from one hundred age-
matched, unrelated normal controls was tested by CSGE to 
confi rm the absence of the identifi ed mutations in the normal 
population. 
In the BRCA1 gene, 15 mutations were identifi ed; thus, 
the mutation frequency of BRCA1 was 24.6% (15/61) (table 
1). Of the BRCA1 mutations identifi ed, there were three 
novel mutations which have not been reported earlier. The 
fi rst novel mutation 295delCA has a deletion of two base 
pairs resulting in a frame shift with the generation of a 
translation stop at downstream codon 64 (fi gure 1 panels A, 
B and C). The second novel mutation 4213delT (L1365X) 
has a single base deletion, which results in the conversion 
of the leucine codon (TTA) at position 1365 to a stop codon 
TAG (fi gure 1 panels D, E and F). The third novel mutation 
Table 1. BRCA1 and BRCA2 mutations in Indian families with familial breast and/or ovarian cancer 
Patient ID Nucleotide 
change
Exon Codon 
affected
Termination 
codon
Mutation type Breast/ovarian 
cancer
BIC entry
BRCA1 mutations
KP-2 185delAG 2 23 39 FS Breast/ovarian 
cancer
Yes
KP-14 185delAG 2 23 39 FS Breast cancer Yes
KP-17 185delAG 2 23 39 FS Ovarian 
cancer
Yes
KP-21 185delAG 2 23 39 FS Breast/ovarian 
cancer
Yes
KP-29 185delAG 2 23 39 FS Breast cancer Yes
KP-36 185delAG 2 23 39 FS Breast cancer Yes
KP-37 185delAG 2 23 39 FS Breast cancer Yes
KP-39 185delAG 2 23 39 FS Breast cancer Yes
KP-58 185delAG 2 23 39 FS Breast cancer Yes
KP-60 185delAG 2 23 39 FS Ovarian 
cancer
Yes
KP-13 295delCA 5 60 64 FS Breast/ovarian 
cancer
No
KP-19 2983C→A 11 S955X 955 NS Breast cancer Yes
KP-30 4213delT 11 L1365X 1365 NS Breast cancer No
KP-1 5267T→G 18 Y1716X 1716 NS Breast/ovarian 
cancer
No
KP-9 3450delCAAG 11 1111 1115 FS Ovarian 
cancer 
Yes
BRCA2 mutations
KP-7 4866InsT 11 D1547X 1547 FS Ovarian 
cancer 
No
KP-8 6079delAGTT 11 1951 1961 FS Breast cancer Yes
FS, frame shift mutation; NS, nonsense mutation; BIC, breast cancer information core.
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Figure 1. For caption, see page No. 419.
5267T→G (Y1716X) is a transversion mutation resulting in 
the conversion of the tyrosine codon (TAT) at position 1716 
to a stop codon TAG (fi gure 1 panels G, H and I). Three 
more mutations were identifi ed in BRCA1, which have 
previously been reported. These are 185delAG, 2983C→
A and 3450delCAAG. Of these, 185delAG was found in 10 
patients, thus occurring at a very high frequency of 16.4% 
(10/61) (fi gure 1 panels J, K and L). It is interesting to note 
that this mutation occurs at a very high frequency of 18.0% 
among breast/ovarian cancer families of Ashkenazi Jews 
and among 1% of Ashkenazi Jews in the general population 
(Struewing et al. 1995; Phelan et al. 2002). 
In the BRCA2 gene, two mutations were identifi ed, thus 
the mutation frequency was 3.28% (2/61) (table 1). Of 
these two BRCA2 mutations, one is novel while the other 
is a reported mutation. The novel mutation is an insertion 
mutation (4866insT) which results in the conversion of an 
aspartic acid codon (GAT) to a stop codon TGA at position 
1547 (D1547X) (fi gure 1 M, N, and O). The other previously 
reported mutation found in BRCA2 is a four-base pair 
deletion 6079delAGTT. 
We further analysed the frequency of BRCA1 and BRCA2 
mutations among different types of cancer as well as age 
groups. Of the families with ovarian cancer, 40.0% had 
mutations, while in families with breast cancer, mutations 
were present in 23.7% of the families. In families with 
breast and ovarian cancer, mutations were present in 30.8%, 
suggesting that BRCA1 and BRCA2 mutations are more 
often associated with ovarian cancer families. Upon analysis 
of different age groups, we found that 23.33% of mutations 
occurred in those ≤40 years and 32.25% in those >40 years. 
While BRCA1 mutations were found in both the age groups, 
BRCA2 mutations were found only in those ≤40 years. 
4. Discussion
In this study, 61 breast/ovarian cancer patients with a family 
history of breast/ovarian cancer were studied for BRCA1 and 
BRCA2 mutations by CSGE. Screening for mutations carried 
out by several groups worldwide suggests a signifi cant 
variation of the relative contribution of BRCA1 and BRCA2 
genes to hereditary cancer between populations (Levy-
Lahad and Friedman 2007). The contribution of BRCA1 and 
BRCA2 mutations pertaining to familial breast and/or ovarian 
cancer in Indian women remains largely unexplored. The 
few studies that have been reported, including one from our 
laboratory, are small studies, and suggest a need to screen for 
mutations in a large number of families with familial breast 
and ovarian cancer (Kumar et al. 2002; Saxena et al. 2002; 
Rajkumar et al. 2003; Valarmathi et al. 2003, 2004; Hedau 
et al. 2004; Saxena et al. 2006). Even though Saxena et al. 
(2006) screened 204 patients, this study included only 34 
families with a positive family history. This set also included 
105 families with early-onset breast cancer. Since early onset 
is a feature of inherited breast cancer involving BRCA1 and 
BRCA2 mutations, families with an early onset of breast 
cancer are generally considered for BRCA1 and BRCA2 
mutation screening programmes. However, it is not ideal 
to include such families in BRCA1 and BRCA2 mutation 
screening in India because of the following reason. The 
average age of breast cancer patients in various population-
based registries in India has been reported to be 50–53 
years compared with 61 years among American women 
(ICMR 2001; Parkin et al. 2002). This is a very important 
point, considering the fact that approximately 90% of breast 
cancer is of the sporadic type. Therefore, including patients 
with early-onset breast cancer in mutation screening studies 
may undermine estimations of the frequency of BRCA1 and 
BRCA2 mutations. Thus, our report becomes the largest 
Indian study with 61 patients from families with a positive 
history of breast and/or ovarian cancer. 
Based on this study, the frequency of BRCA1 and BRCA2 
mutations among Indian women with familial breast and 
ovarian cancers is found to be 24.60% (15/61) and 3.28% 
(2/61), respectively. Reports worldwide suggest that 
mutations in BRCA1 and BRCA2 are responsible for 20% of 
familial cases of breast and/or ovarian cancer (Wooster and 
Weber 2003). While the contribution of BRCA1 mutations to 
familial breast cancer is in the same range as those of other 
reports published worldwide, the contribution of BRCA2 
mutations seems rather low among Indian women. However, 
the lower contribution of BRCA2 mutation to familial breast 
cancer development is supported by earlier studies from 
India (Saxena et al. 2002; Rajkumar et al. 2003; Valarmathi 
et al. 2004; Saxena et al. 2006). 
All BRCA1 mutations identifi ed were truncating 
mutations. While three of them were deletion mutations 
leading to the generation of a stop codon further downstream, 
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Figure 1. Panels A, D, G, J and M. Ethidium bromide-stained gel for conformation-sensitive gel electrophoresis of PCR products. Panel 
A. BRCA1 exon 5 of normal (lane 2), KP2 (lane 3), KP3 (lane 4), KP4 (lane 5) and KP13 (lane 6). Panel D. BRCA1 exon 11 of KP25 (lane 
1), KP26 (lane 2), KP27 (Lane 3), KP28 (lane 4), KP29 (lane 5) and KP30 (lane 6). Panel G. BRCA1 exon18 of normal (lane 2 and 3), 
KP3 (lane 3), KP10 (Lane 4) and KP1 (lane 6 and 7). Panel J. BRCA1 exon 2 of normal (lane 2), KP2 (lane 3), KP3 (lane 4), KP4 (lane 5) 
and KP5 (lane 6). Panel M. BRCA2 exon 11 of normal (lane 2), KP4 (lane 3), KP5 (Lane 4), KP6 (lane 5) and KP7 (lane 6). White arrows 
indicate the heteroduplex bands. Panels B, E, H, K and N. Electropherogram of DNA sequencing of BRCA1 exons 5, 11, 18, 2 and BRCA2 
exon 11, respectively, from normal individuals. Panels C,F, I, L and O. Electropherogram of DNA sequencing of BRCA1 exon 5 from KP13 
(panel C), BRCA1 exon 11 from KP30 (panel F), BRCA1 exon 18 from KP1 (panel I), BRCA1 exon 2 from KP2 (panel L) and BRCA2 exon 
11 from KP7 (panel O). The mutation type and location are shown. 
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the other three were nonsense mutations resulting in the 
generation of a stop codon at the mutation site. Interestingly, 
three of the BRCA1 mutations found in this study were novel 
mutations. In the case of BRCA2 as well, the two mutations 
identifi ed were of the truncating type. While one of them is 
a four base-pair deletion resulting in the generation of stop 
codon downstream, the other is a one base-pair insertion 
leading to the formation of a stop codon at the mutation site 
itself. One of the BRCA2 mutations was found to be a novel 
type not reported earlier. 
We also found that families with ovarian cancer had 
mutations in the BRCA1 and BRCA2 genes more often than 
families with breast cancer. BRCA1 and BRCA2 germline 
mutations were found in 43.0% of families with ovarian 
cancer, with BRCA1 mutations being four-fold more 
common than BRCA2 mutations (Gayther et al. 1999). 
While BRCA1 mutations were found in all age groups, 
BRCA2 mutations were found only in the age group of ≤40 
years, suggesting perhaps that BRCA2 defects more often 
lead to early-onset breast and ovarian cancer. In contrast to 
this observation, BRCA2 mutations were found to contribute 
to fewer cases of breast cancer among young women than 
mutations in BRCA1 (Krainer et al. 1997). 
Interestingly, we found the BRCA1 mutation 185delAG 
among 10/61 patients; the frequency of this mutation 
was thus 16.4%. Different specifi c mutations in BRCA1 
and BRCA2 occurring at a high frequency in various 
ethnic groups have been reported. In Israel, three specifi c 
mutations: 185delAG, 5382insC in BRCA1, and 6174delT 
in BRCA2 were reported to occur in 36% of breast/ovarian 
cancer families (Levy-Lahad et al. 1997). Of these, 
185delAG was found to occur at a very high frequency of 
18.0% in families of Ashkenazi Jews with breast/ovarian 
cancer (Phelan et al. 2002). This mutation also occurs at a 
frequency of 1% among the Ashkenazi general population, 
thus making it one of the founder mutations responsible for 
its increased association with inherited breast/ovarian cancer 
(Struewing et al. 1995). 
However, 185delAG mutation has been reported to occur 
at varying frequencies among families with breast/ovarian 
cancer in different populations. A very high frequency of 
31.6% has been reported among non-Jewish Americans 
of Spanish ancestry from the San Luis Valley, Colorado 
(Mullineaux et al. 2003). However, this mutation has been 
found to occur at a varying low frequency (1.13–5.9%) 
among white Americans, the Spanish from Spain, Polish, 
Iranian, Pakistani and Turkish women (Grzybowska et al. 
2002; Shih et al. 2002; Guran et al. 2005; Weitzel et al. 2005; 
Mehdipour et al. 2006; Rashid et al. 2006). Interestingly, 
the 185delAG mutation was not found among Chinese and 
Japanese families with breast cancer (Ikeda et al. 2001; Zhi et 
al. 2002). Although previous studies, including one from our 
laboratory, reported the occurrence of 185delAG mutation 
among Indian women, the high frequency of occurrence of 
185delAG mutation reported in this study, similar to that of 
Ashkenazi Jews, is notable. Haplotype analysis is required 
to identify the origin of this mutation among Indian women. 
Preliminary haplotype analysis revealed that 185delAG 
mutation among Indian women may have an independent 
origin as their haplotype was different from that of Ashkenazi 
Jews (data not shown). However, these data remain to be 
confi rmed by studying a larger number of individuals. In 
addition, it would be interesting to test the carrier frequency 
of 185delAG among different religious/ethnic/geographical 
groups of the general Indian population to further understand 
its prevalence and origin. 
Thus, this study suggests that the mutation spectrum and 
prevalence of the BRCA1 and BRCA2 genes in the south 
Indian population have some similarities and differences 
between what is observed in other populations. This study 
also emphasizes the importance of a positive family history 
as the basis for BRCA1 and BRCA2 mutation screening, 
particularly among patients with early-onset disease. 
With appropriate genetic counselling, patients and pre-
symptomatic mutation carriers would be able to make better 
medical and surgical decisions. 
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